Search Results - "PATTERSON, Adam V"

Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects by Lu, Xiaoyun, Chen, Hao, Patterson, Adam V, Smaill, Jeff B, Ding, Ke

“…Hepatocellular carcinoma (HCC) is a lethal disease with limited therapeutic options and a particularly poor prognosis. Aberrant fibroblast growth factor 19…”
Get full text

TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure by Kalyukina, Maria, Yosaatmadja, Yuliana, Middleditch, Martin J., Patterson, Adam V., Smaill, Jeff B., Squire, Christopher J.

“…1‐[(3S)‐3‐[4‐Amino‐3‐[2‐(3,5‐dimethoxyphenyl)ethynyl]‐1H‐pyrazolo[3,4‐d]pyrimidin‐1‐yl]‐1‐pyrrolidinyl]‐2‐propen‐1‐one (TAS‐120) is an irreversible inhibitor…”
Get full text

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes by Estrada-Bernal, Adriana, Le, Anh T, Doak, Andrea E, Tirunagaru, Vijaya G, Silva, Shevan, Bull, Matthew R, Smaill, Jeff B, Patterson, Adam V, Kim, Chul, Liu, Stephen V, Doebele, Robert C

“…Approved therapies for exon 20, mutations, and fusions are currently lacking for non-small cell lung cancer and other cancers. Tarloxotinib is a prodrug that…”
Get full text

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed by Yosaatmadja, Yuliana, Silva, Shevan, Dickson, James M., Patterson, Adam V., Smaill, Jeff B., Flanagan, Jack U., McKeage, Mark J., Squire, Christopher J.

“…The discovery of genetic drivers of lung cancer in patient sub-groups has led to their use as predictive biomarkers and as targets for selective drug therapy…”
Get full text

Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility by Williams, Elsie M, Little, Rory F, Mowday, Alexandra M, Rich, Michelle H, Chan-Hyams, Jasmine V E, Copp, Janine N, Smaill, Jeff B, Patterson, Adam V, Ackerley, David F

“…This review examines the vast catalytic and therapeutic potential offered by type I (i.e. oxygen-insensitive) nitroreductase enzymes in partnership with…”
Get more information

Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy by Fu, Zhe, Mowday, Alexandra M, Smaill, Jeff B, Hermans, Ian F, Patterson, Adam V

“…The magnitude of the host immune response can be regulated by either stimulatory or inhibitory immune checkpoint molecules. Receptor-ligand binding between…”
Get full text

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials by Spiegelberg, Linda, Houben, Ruud, Niemans, Raymon, de Ruysscher, Dirk, Yaromina, Ala, Theys, Jan, Guise, Christopher P., Smaill, Jeffrey B., Patterson, Adam V., Lambin, Philippe, Dubois, Ludwig J.

“…•Hypoxia-activated prodrugs have yielded promising results up to phase II trials.•Implementation of hypoxia-activated prodrugs in the clinic has not been…”
Get full text

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302 by Meng, Fanying, Evans, James W, Bhupathi, Deepthi, Banica, Monica, Lan, Leslie, Lorente, Gustavo, Duan, Jian-Xin, Cai, Xiaohong, Mowday, Alexandra M, Guise, Christopher P, Maroz, Andrej, Anderson, Robert F, Patterson, Adam V, Stachelek, Gregory C, Glazer, Peter M, Matteucci, Mark D, Hart, Charles P

“…TH-302 is a 2-nitroimidazole triggered hypoxia-activated prodrug (HAP) of bromo-isophosphoramide mustard currently undergoing clinical evaluation. Here, we…”
Get full text

Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623 by Sharrock, Abigail V, Mumm, Jeff S, Williams, Elsie M, Čėnas, Narimantas, Smaill, Jeff B, Patterson, Adam V, Ackerley, David F, Bagdžiūnas, Gintautas, Arcus, Vickery L

“…Bacterial nitroreductase enzymes capable of activating imaging probes and prodrugs are valuable tools for gene-directed enzyme prodrug therapies and targeted…”
Get full text

The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3 by GUISE, Christopher P, ABBATTISTA, Maria R, DONATE, Fernando, WILSON, William R, PATTERSON, Adam V, SINGLETON, Rachelle S, HOLFORD, Samuel D, CONNOLLY, Joanna, DACHS, Gabi U, FOX, Stephen B, POLLOCK, Robert, HARVEY, Justin, GUILFORD, Parry

“…PR-104, currently in phase II clinical trials, is a phosphate ester pre-prodrug which is converted in vivo to its cognate alcohol, PR-104A, a prodrug designed…”
Get full text

Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents by Omran, Ziad, Guise, Chris P., Chen, Linwei, Rauch, Cyril, Abdalla, Ashraf N., Abdullah, Omeima, Sindi, Ikhlas A., Fischer, Peter M., Smaill, Jeff B., Patterson, Adam V., Liu, Yuxiu, Wang, Qingmin

“…Phenanthroindolizidines, such as antofine and tylophorine, are a family of natural alkaloids isolated from different species of Asclepiadaceas. They are…”
Get full text

Bystander or no bystander for gene directed enzyme prodrug therapy by Dachs, Gabi U, Hunt, Michelle A, Syddall, Sophie, Singleton, Dean C, Patterson, Adam V

“…Gene directed enzyme prodrug therapy (GDEPT) of cancer aims to improve the selectivity of chemotherapy by gene transfer, thus enabling target cells to convert…”
Get full text

Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104 by PATTERSON, Adam V, FERRY, Dianne M, SHANGJIN YANG, DENNY, William A, WILSON, William R, EDMUNDS, Shelley J, YONGCHUAN GU, SINGLETON, Rachelle S, PATEL, Kashyap, PULLEN, Susan M, HICKS, Kevin O, SYDDALL, Sophie P, ATWELL, Graham J

“…Purpose: Hypoxia is a characteristic of solid tumors and a potentially important therapeutic target. Here, we characterize the mechanism of action and…”
Get full text

Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling by Jackson-Patel, Victoria, Liu, Emily, Bull, Matthew R, Ashoorzadeh, Amir, Bogle, Gib, Wolfram, Anna, Hicks, Kevin O, Smaill, Jeff B, Patterson, Adam V

“…Hypoxia-activated prodrugs are bioactivated in oxygen-deficient tumour regions and represent a novel strategy to exploit this pharmacological sanctuary for…”
Get full text

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity by Guise, Chris P, Abbattista, Maria R, Anderson, Robert F, Li, Dan, Taghipouran, Rana, Tsai, Angela, Lee, Su Jung, Smaill, Jeff B, Denny, William A, Hay, Michael P, Wilson, William R, Hicks, Kevin O, Patterson, Adam V

“…Hypoxia is an adverse prognostic feature of solid cancers that may be overcome with hypoxia-activated prodrugs (HAPs). Tirapazamine (TPZ) is a HAP which has…”
Get full text

The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia by Toscan, Cara E., McCalmont, Hannah, Ashoorzadeh, Amir, Lin, Xiaojing, Fu, Zhe, Doculara, Louise, Kosasih, Hansen J., Cadiz, Roxanne, Zhou, Anthony, Williams, Sarah, Evans, Kathryn, Khalili, Faezeh, Cai, Ruilin, Yeats, Kristy L., Gifford, Andrew J., Pickford, Russell, Mayoh, Chelsea, Xie, Jinhan, Henderson, Michelle J., Trahair, Toby N., Patterson, Adam V., Smaill, Jeff B., de Bock, Charles E., Lock, Richard B.

“…T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that expresses high levels of the enzyme aldo-keto reductase family 1…”
Get full text

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3 by Abbattista, Maria R, Ashoorzadeh, Amir, Guise, Christopher P, Mowday, Alexandra M, Mittra, Rituparna, Silva, Shevan, Hicks, Kevin O, Bull, Matthew R, Jackson-Patel, Victoria, Lin, Xiaojing, Prosser, Gareth A, Lambie, Neil K, Dachs, Gabi U, Ackerley, David F, Smaill, Jeff B, Patterson, Adam V

“…PR-104 is a phosphate ester pre-prodrug that is converted in vivo to its cognate alcohol, PR-104A, a latent alkylator which forms potent cytotoxins upon…”
Get full text

Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications by Ashoorzadeh, Amir, Mowday, Alexandra M, Guise, Christopher P, Silva, Shevan, Bull, Matthew R, Abbattista, Maria R, Copp, Janine N, Williams, Elsie M, Ackerley, David F, Patterson, Adam V, Smaill, Jeff B

“…PR-104A is a dual hypoxia/nitroreductase gene therapy prodrug by virtue of its ability to undergo either one- or two-electron reduction to its cytotoxic…”
Get full text

Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors by Lu, Xiaoyun, Smaill, Jeff B, Patterson, Adam V, Ding, Ke

“…Small molecule covalent kinase inhibitors (CKIs) have entered a new era in drug discovery, which have the advantage for sustained target inhibition and high…”
Get full text

Improved Strategy for the Synthesis of the Anticancer Agent Culicinin D by Stach, Michaela, Weidkamp, Andreas J., Yang, Sung-Hyun, Hung, Kuo-yuan, Furkert, Daniel P., Harris, Paul W. R., Smaill, Jeff B., Patterson, Adam V., Brimble, Margaret A.

“…The anticancer peptaibol culicinin D was synthesised via a newly developed pathway. This route included an improved attachment of a C‐terminal amino acid…”
Get full text